Nupur Ghoshal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5592895/publications.pdf

Version: 2024-02-01

567281 501196 52 845 15 28 citations h-index g-index papers 56 56 56 1108 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Proposed research criteria for prodromal behavioural variant frontotemporal dementia. Brain, 2022, 145, 1079-1097.	7.6	30
2	The contribution of behavioral features to caregiver burden in FTLD spectrum disorders. Alzheimer's and Dementia, 2022, 18, 1635-1649.	0.8	9
3	Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Reports Medicine, 2022, 3, 100607.	6.5	21
4	Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia. Neurology, 2022, , 10.1212/WNL.00000000000582.	1.1	0
5	Differences in Motor Features of <i>C9orf72</i> , <i>MAPT</i> , or <i>GRN</i> Variant Carriers With Familial Frontotemporal Lobar Degeneration. Neurology, 2022, 99, .	1.1	5
6	Brain volumetric deficits in <i>MAPT</i> mutation carriers: a multisite study. Annals of Clinical and Translational Neurology, 2021, 8, 95-110.	3.7	21
7	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology, 2021, 96, e2296-e2312.	1.1	52
8	Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia. Cortex, 2021, 139, 99-115.	2.4	12
9	<i>MAPT</i> R406W increases tau T217 phosphorylation in absence of amyloid pathology. Annals of Clinical and Translational Neurology, 2021, 8, 1817-1830.	3.7	11
10	Demographic and psychosocial factors associated with the decision to learn mutation status in familial frontotemporal dementia and the impact of disclosure on mood. Alzheimer's and Dementia, 2021, 17, e050692.	0.8	0
11	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIHâ€EXAMINER as a potential clinical trial endpoint. Alzheimer's and Dementia, 2020, 16, 11-21.	0.8	32
12	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 37-48.	0.8	38
13	The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology. Alzheimer's and Dementia, 2020, 16, 22-36.	0.8	32
14	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
15	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 49-59.	0.8	27
16	Studying the natural history of frontotemporal lobar degeneration (FTLD): The ARTFL LEFFTDS longitudinal FTLD (ALLFTD) protocol. Alzheimer's and Dementia, 2020, 16, e045482.	0.8	0
17	Plasma neurofilament light chain levels reflect caregiver burden and social cognition measures in familial frontotemporal lobar degeneration (FTLD). Alzheimer's and Dementia, 2020, 16, e046247.	0.8	0
18	Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases. Alzheimer's and Dementia, 2020, 16, 118-130.	0.8	43

#	Article	IF	Citations
19	Utility of the global CDR $<$ sup $>$ Â $@sup> plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium. Alzheimer's and Dementia, 2020, 16, 106-117.$	0.8	81
20	Revised Self-Monitoring Scale. Neurology, 2020, 94, e2384-e2395.	1.1	23
21	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. Neurobiology of Aging, 2019, 83, 54-62.	3.1	14
22	O4â€03â€01: FRONTOTEMPORAL LOBAR DEGENERATION RESEARCH IN NORTH AMERICA: PROGRESS IN THE ARTFL/LEFFTDS CONSORTIA. Alzheimer's and Dementia, 2019, 15, P1234.	0.8	0
23	Nonlinear Zâ€score modeling for improved detection of cognitive abnormality. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 797-808.	2.4	12
24	P1â€433: GRAY MATTER DEFICITS IN SYMPTOMATIC AND PRESYMPTOMATIC <i>MAPT</i> MUTATION CARRIERS. Alzheimer's and Dementia, 2018, 14, P475.	0.8	0
25	P1â€281: NONLINEAR Nâ€6CORE ESTIMATION FOR ESTABLISHING COGNITIVE NORMS FROM THE NATIONAL ALZHEIMER'S COORDINATING CENTER (NACC) DATASET. Alzheimer's and Dementia, 2018, 14, P390.	0.8	1
26	O2â€14â€02: THE CLINICAL SPECTRUM OF FRONTOTEMPORAL LOBAR DEGENERATION IN NORTH AMERICA: BASELINE CHARACTERISTICS OF THE FIRST 912 PARTICIPANTS FROM THE ADVANCING RESEARCH AND TREATMENT IN FTLD (ARTFL) CLINICAL RESEARCH CONSORTIUM. Alzheimer's and Dementia, 2018, 14, P656.	0.8	0
27	O1â€08â€01: THE NIHâ€EXAMINER IS SENSITIVE TO COGNITIVE CHANGES IN ASYMPTOMATIC AND MILDLY SYMPTOMATIC FAMILIAL FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2018, 14, P235.	0.8	O
28	Acquired mania associated with a left temporal meningioma. Bipolar Disorders, 2018, 20, 774-777.	1.9	0
29	Preclinical Alzheimer's disease and longitudinal driving decline. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 74-82.	3.7	44
30	[P4–189]: SYMPTOM ONSET IN GENETIC FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1337.	0.8	2
31	[ICâ€Pâ€180]: FLORTAUCIPIR TAUâ€PET SPECIFICITY IS MAINTAINED IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CREUTZFELDTâ€JAKOB DISEASE. Alzheimer's and Dementia, 2017, 13, P134.	0.8	0
32	[P1â€"254]: CHARACTERISTICS AND PROGRESS ON THE INITIAL 209 SUBJECTS IN THE LONGITUDINAL EVALUATION OF FAMILIAL FRONTOTEMPORAL DEMENTIA SUBJECTS (LEFFTDS) PROTOCOL. Alzheimer's and Dementia, 2017, 13, P345.	0.8	0
33	[P1â€"317]: QUALITY OF LIFE AMONG SUBJECTS AND INFORMANTS IN FAMILIAL FRONTOTEMPORAL DEMENTIA: PRELIMINARY DATA IN THE LEFFTDS COHORT. Alzheimer's and Dementia, 2017, 13, P376.	0.8	O
34	[P2â€"281]: CAREGIVER BURDEN IN FAMILIAL FRONTOTEMPORAL DEMENTIA SUBJECTS: PRELIMINARY DATA IN THE LEFFTDS COHORT. Alzheimer's and Dementia, 2017, 13, P722.	0.8	0
35	[P2â€"303]: ADVANCING RESEARCH AND TREATMENT IN FRONTOTEMPORAL LOBAR DEGENERATION (ARTFL) NORTH AMERICAN RARE DISEASE CLINICAL RESEARCH CONSORTIUM: PROGRESS AND CHARACTERIZATION OF INITIAL PARTICIPANTS. Alzheimer's and Dementia, 2017, 13, P733.	0.8	O
36	P1â€254: Principal Component Analysis of [18F]â€Avâ€1451 TAU Pet in Alzheimer'S Disease and Frontotemp Dementia. Alzheimer's and Dementia, 2016, 12, P507.	oral 0.8	0

#	Article	IF	Citations
37	P3â€234: Similarities and Differences in Patterns of [F18]â€AVâ€1451 and [F18]â€FDG in Frontotemporal Deme Alzheimer's and Dementia, 2016, 12, P915.	ntia 0.8	0
38	P4â€150: Preclinical Alzheimer's Disease Predicts Longitudinal Onset of Driving Difficulties Among Cognitively Normal Persons. Alzheimer's and Dementia, 2016, 12, P1071.	0.8	0
39	IC-P-204: Principal Component Analysis of [18F]-Av-1451 TAU PET in Alzheimer's Disease and Frontotemporal Dementia. , 2016, 12, P145-P146.		0
40	ICâ€Pâ€206: Similarities and Differences in Patterns of [F18]â€Avâ€1451 And [F18]â€FDG in Frontotemporal Dementia. Alzheimer's and Dementia, 2016, 12, P147.	0.8	0
41	Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels. American Journal of Geriatric Psychiatry, 2016, 24, 1095-1104.	1.2	95
42	Development and interval testing of a naturalistic driving methodology to evaluate driving behavior in clinical research. F1000Research, 2016, 5, 1716.	1.6	16
43	P1-283: The relationship between mood states and preclinical Alzheimer disease in older adults. , 2015, 11, P463-P463.		0
44	P2-130: Amyloid imaging and cerebrospinal fluid biomarkers predict driving performance in preclinical Alzheimer's disease., 2015, 11, P533-P534.		1
45	P3-309: Advancing research and treatment of frontotemporal lobar degeneration (ARTFL): Preparing for clinical trials for ftld in north america., 2015, 11, P755-P755.		0
46	P1-281: Adults 65 and older use potentially distracting electronic devices while driving., 2015, 11, P463-P463.		0
47	Adults Aged 65 and Older Use Potentially Distracting Electronic Devices While Driving. Journal of the American Geriatrics Society, 2015, 63, 1251-1254.	2.6	5
48	O5-03-01: Longitudinal evaluation of familial frontotemporal dementia subjects (LEFFTDS): Subject characteristics, aims, and methodology., 2015, 11, P318-P319.		0
49	Whipple's Disease Masquerades as Dementia With Lewy Bodies. Alzheimer Disease and Associated Disorders, 2015, 29, 85-89.	1.3	7
50	Variably Protease-sensitive Prionopathy in an Apparent Cognitively Normal 93-Year-Old. Alzheimer Disease and Associated Disorders, 2015, 29, 173-176.	1.3	6
51	Unravelling the mysteries of frontotemporal dementia. Missouri Medicine, 2013, 110, 411-6.	0.3	0
52	Codistribution of Amyloid \hat{l}^2 Plaques and Spongiform Degeneration in Familial Creutzfeldt-Jakob Disease With the E200K-129M Haplotype. Archives of Neurology, 2009, 66, 1240-6.	4.5	29